BEIJING, June 23, 2022 /PRNewswire/ On June 23, Berry Oncology, a global leading company specialized in genomic testing and early cancer screening, announced the launch of its innovative one-time precision product HIFI Pan-Cancer Screening, which is an early multi-cancer screening product developed based on the company's proprietary HIFI technology platform. With one single testing, the product can accurately detect 6 high-risk and high-incident cancers in China that include lung cancer, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, and colorectal cancer, with a global leading performance of 87.58% sensitivity, 99.09% specificity and 82% traceability accuracy. Cancer has become a global public health challenge. According to the 2020 global cancer burden data released by the International Agency for Research on Cancer (IARC), there were 19.29 million new cancer cases and 9.96 million cancer deaths worldwide in 2020, while the numbers in China were 4.57 million
If you ask anyone how to reduce the mortality rate of cancer patients, the answer may vary from person to person. Yet early detection and intervention probably will occur in most people's answers to that question.
Berry Oncology, a leading Chinese company in genetic testing and early screening of tumors, plans to launch an early cancer screening product within the year that is capable in detecting six prevalent tumor types in China at one time, according to a senior executive of the company on Wednesday.
/PRNewswire/ Berry Oncology, a leading company in the global industry for genetic testing and early screening of tumors, recently launched a HIFI system..